Antisense oligonucleotides for inhibiting herpesviruses

• US 5,248,670 A
• Filed: 02/26/1990
• Issued: 09/28/1993
• Est. Priority Date: 02/26/1990
• Status: Expired due to Term

• Current Assignee: ISIS Pharmaceuticals Incorporated
• Original Assignee: ISIS Pharmaceuticals Incorporated
• Inventors: Ecker, David J., Crooke, Stanley T., Mirabelli, Christopher K., Draper, Kenneth G.
• Primary Examiner(s): Brown, Johnnie R.
• Assistant Examiner(s): Kunz, Gary L.
• Application Number:
  US07/485,297
• Time in Patent Office: 1,310 Days
• Field of Search: 536/27, 435/6, 514/34, 935/78
• US Class Current: 514/44.00A
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/22 for herpes viruses
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C12N 15/1133 against herpetoviridae, e.g. HSV
• CPC Class Codes: C12N 2310/3125 Methylphosphonates
• CPC Class Codes: C12N 2310/315 Phosphorothioates
• CPC Class Codes: C12N 2710/16622 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

Antisense oligonucleotides are disclosed having a length of 15-30 nucleotides containing the CAT sequence and hybridizable to herpes simplex virus type I gene UL13, UL39, or UL40. These antisense oligomers inhibit the replication of the virus at least three-fold. Pharmaceutical compositions containing these oligonucleotides as the active ingredients are also disclosed.

Claims

1. An oligonucleotide or an oligonucleotide having at least one phosphorothioate internucleotide bond consisting essentially of 15 to 30 nucleotides in length, which contains the CAT sequence and which is specifically hybridizable under stringent conditions to the translation initiation region of an open reading frame of a herpes simplex virus type 1 gene selected from the group consisting of UL13, UL39, and UL40, and which is capable of reducing viral yield at least three-fold.

2. A pharmaceutical composition comprising an oligonucleotide of claim 1 and a pharmaceutically acceptable carrier.

3. An oligonucleotide or an oligonucleotide having at least one phosphorothioate internucleotide bond consisting essentially of a sequence selected from the group consisting of

View Dependent Claims (4)

4. A pharmaceutical composition comprising an oligonucleotide of claim 3 and a pharmaceutically acceptable carrier.